Colleen M. Nash is an Adult-Gerontology Acute Care Nurse Practitioner, Northwestern Memorial Hospital, 251 E Huron St, Chicago, IL 60611 (
AACN Adv Crit Care. 2021 Jun 15;32(2):137-145. doi: 10.4037/aacnacc2021299.
Vasoplegic syndrome is a rising problem affecting morbidity and mortality in patients undergoing cardiac surgery. Vasoplegia is a vasodilatory, shocklike syndrome characterized by decreased systemic vascular resistance, normal to high cardiac index, and hypotension refractory to fluid resuscitation and vasopressors. This review describes the presentation, physiology, risk factors, treatments, and implications of vasoplegia after cardiac surgery. No standardized methods for diagnosing and treating vasoplegia are available. Vasoplegia is caused by surgical trauma, systemic inflammation, and vascular dysregulation. Patients with comorbidities and those undergoing complex surgical procedures are at increased risk for vasoplegia. The use of β-blockers is protective. Vasoplegia is potentially reversible. Vasopressin is likely the most effective first-line vasopressor, and the use of methylene blue and/or hydroxocobalamin may restore vascular tone. Alternative therapies such as methylene blue and hydroxocobalamin show promise, but additional research and education are needed.
血管麻痹综合征是一种影响心脏手术患者发病率和死亡率的日益严重的问题。血管麻痹是一种血管扩张性、休克样综合征,其特征为全身血管阻力降低、心指数正常至升高,以及对液体复苏和血管加压药治疗的低血压反应。本文描述了心脏手术后血管麻痹的表现、生理学、危险因素、治疗方法和影响。目前尚无诊断和治疗血管麻痹的标准化方法。血管麻痹是由手术创伤、全身炎症和血管调节异常引起的。合并症患者和接受复杂手术的患者发生血管麻痹的风险增加。β受体阻滞剂具有保护作用。血管麻痹是潜在可逆转的。血管加压素可能是最有效的一线血管加压药,使用亚甲蓝和/或羟钴胺可能恢复血管张力。替代疗法如亚甲蓝和羟钴胺显示出希望,但需要进一步的研究和教育。